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Recent advances in drug delivery and controlled release had a great impact on bioscience, medicine and
tissue engineering. Consequently, a variety of advanced drug delivery vehicles either have already
reached the market or are approaching the phase of commercial production. Progressive growth of the
drug delivery market has led to the necessity to earnestly concern about economically viable,
up-scalable and sustainable technologies for a large-scale production of drug delivery carriers. We have
identified three attractive natural sources of drug carriers: aluminosilicate clays, minerals of calcium
carbonate, and cellulose. Three classes of drug delivery carriers derived from these natural materials are
halloysite nanotubes, vaterite crystals and nanocellulose. These carriers can be produced using ‘‘green’’
technologies from some of the most abundant sources on the Earth and have extremely high potential
to meet all criteria applied for the manufacture of modern delivery carriers. We provide an up-to-date
snapshot of these drug delivery vehicles towards their use for bioapplications, in particular for drug
delivery and tissue engineering. The following research topics are addressed: (i) the availability, sources
and methodologies used for production of these drug delivery vehicles, (ii) the drug loading and release
mechanisms of these delivery vehicles, (iii) in vitro, in vivo, and clinical studies on these vehicles, and
(iv) employment of these vehicles for tissue engineering. Finally, the prospects for vehicles’ further
development and industrialisation are critically assessed, highlighting most attractive future research
directions such as the design of third generation active biomaterials.
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1. Introduction
During the last few decades, emerging new drug delivery
technologies allowed control of the design and fabrication of
various materials at the nanoscale, which revolutionised bio-
medical science and significantly impacted the fields of nano-
medicine, diagnostics and tissue engineering. Since drug
delivery allows controlled transfer of drugs to the target with
a high efficiency and minimised adverse side effects, drug
delivery vehicles have progressively become an integral part of
modern medications. Besides this, the costs for the develop-
ment of new clinical therapeutics might be estimated as $100–
500 million, while the development of new delivery vehicles is
much less expensive and generally gives significantly quicker
profit.1 This provides an additional economic reason for the
boost of drug delivery technologies.
Despite their promising prospects and their success in drug
delivery research, new delivery vehicles are making their way
from science to the market extremely slow. This is due to
multiple factors, and most of them are not related to science
and range from rather complicated policies and procedures for
Food and Drug Administration (FDA) agency approval to high
fabrication costs that largely pose a manufacturing challenge.
Indeed, sometimes the costs for manufacturing drug delivery
vehicles much exceed the costs for the drug itself. For instance,
liposomal doxorubicin Doxil (the drug widely used for the
treatment of ovarian cancer, sarcoma and myeloma) costs
ca. $130 per unit, which is 40–100 times higher than that of free
doxorubicin (ca. $1.3–3 per unit; USA prices). Another complica-
tion is a multi-step fabrication of drug delivery carriers that is
often challengeable to upscale, at least usingmodern technologies.
For instance, upscaling remains a serious limitation for the
commercialisation of polymeric nanoparticles.2 Finally, the use of
animal and plant sources for the isolation of substances for delivery
carriers (e.g. lipids, biopolymers, proteins) is quite common.3 Low
sustainability of delivery carriers production stimulates scientists to
think about the possible negative environmental impact that the
global production of delivery vehicles may have.4
In view of the above, the quest for alternatives sources for
drug delivery vehicles – minerals, bacteria and waste materials –
resulted in the rise of a new wave of drug delivery research.
Scientists have proposed dozens of novel drug delivery vehicles,
the most important examples of which are clays, minerals of
calcium salts such as carbonates and hydroxyapatites, and cellulose-
based materials. Typical examples of nano- and micro-sized
particles made of such materials are halloysite nanotubes
(HNTs), vaterite CaCO3 (VCC) and nanocellulose (NC).
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All these materials exhibit null to low toxicity, good bio-
compatibility and/or biodegradability. These delivery vehicles
may be loaded with tremendously diverse compounds ranging
from small drugs to macromolecules and from highly hydro-
philic to solely lipophilic encapsulates. Importantly, material
costs required for their production are significantly lower than
those for conventional delivery vehicles (Table 1). A variety of
fabrication technologies proposed during the last few decades
lays a platform for their swift industrialisation.
In addition to lower material costs, production of HNTs and
NC is commonly reduced to their isolation and purification
from abundant sources (Fig. 1), which is generally less expensive
compared to sophisticated methods for the fabrication of conven-
tional vehicles such as liposomes and polymer beads. Calcium
carbonate is also an abundant natural mineral that can be isolated
from natural sources; however, the most common in nature is
calcite, a nonporous polymorph of CaCO3, while mesoporous VCC
(more suitable for biomedical applications) is not so abundant.
Because of low abundance of vaterite in nature, its bottom-up
production is economically more profitable. NC growth by bacteria
is also widely proposed as a sustainable alternative to plant-derived
sources. Moreover, ‘‘green’’ strategies for the production of nano-
cellulose from wood or paper waste5,6 as well as vaterite from
eggshell and seashell waste7,8 are now being widely discussed.
Although these ‘‘sustainable’’ delivery vehicles have not
dislodged their conventional analogies yet, they have rapidly
gained popularity and have extremely high potential to enter
the market of drug delivery vehicles in the nearest future.
In this paper, we discuss the up-to-date knowledge on and
prospects for biomedical use of three naturally derived delivery
vehicles: HNTs, VCC, and NC. All of them have been known for
ages but discovered as drug delivery vehicles quite recently and
witnessed an exponential growth of scientific interest since that
time (Fig. 2). This article aims at uncovering key features of
HNTs, VCC and NC in a comparative manner, revealing their
strong and weak sides for drug delivery and tissue engineering/
regeneration applications, and evaluating the prospects for
their further study and biomedical use.
2. Clay nanotubes
2.1. Clay-based nanomaterials
Among the variety of different minerals, clay minerals are the
most widely used for therapeutic purposes due to their high
specific area, chemical andmechanical stability, biocompatibility
and low toxicity for humans. Nanoclays are largely abundant in
nature, which eliminates the need for their industrial synthesis.
The only exception is LAPONITEs, a synthetic equivalent of
Table 1 Estimated material costs for the production of different drug
delivery vehiclesa
Drug delivery vehicles Price, $ per g of dried weight
Liposomes (DPPC) 90–170
PLGA (50 : 50, 1–2 dL g1) 30–70
Halloysite nanotubes 0.3–0.4
Vaterite CaCO3 0.2–0.4
b
Nanocellulose 0.8–5.5
DPPC – dipalmitoylphosphatidylcholine; PLGA – poly(lactic-co-glycolic
acid). a Lab grade chemicals; prices provided by official distributers –
Sigma Aldrich; Merck; Fisher Scientific; Polysciences; Cellulose Lab;
Avanti Polar Lipids, etc. b Produced from CaCl22H2O and Na2CO3.
Fig. 1 Sustainable sources of nanoclays, calcium carbonate and nanocellulose.
Fig. 2 Annual numbers of scientific research publications on the topics
‘‘halloysite’’, ‘‘calcium carbonate’’ and ‘‘nanocellulose’’ and ‘‘drug delivery’’
or ‘‘tissue engineering’’ in the past two decades (Web of Science Database,
November 2019).
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hectorite produced by Laporte (Netherlands). Other nanoclays
exist in nature; these minerals refer to the group of phyllosilicates,
also called ‘‘sheet silicates’’. Nanoclays are hydrous alumina or
magnesium silicates (sometimes with variable amounts of other
metals) composed of parallel sheets of Si–O tetrahedral and
octahedral sheets containing metal atoms (Al, Mg) coordinated
with the oxygen from Si–O tetrahedra and OH groups.
Nanoclays are very diverse and classified based on the
number of tetrahedral and octahedral sheets per clay layer as
1 : 1, 2 : 1 and 2 : 1 : 1 minerals. Thus, kaolinite and halloysite
(Fig. 3), the polymorphs of Al2Si2O5(OH)4, are 1 : 1 clays in
which one octahedral sheet is bonded to one tetrahedral sheet,
yielding a 7 Å repeat along the z-axis. These layers may have
lateral dimensions from tens of nanometres to micrometres.9
Several layers may interact with each other via electrostatics
and van der Waals interactions, hydrogen bonding or interlayer
cations that ensure the diversity of nanoclays. The mineralogical
properties of nanoclays are described in detail in a recent
review.10
Halloysite is a significant component of many kaolinitic
clays that commonly exists in a mixture with kaolinite, silica,
or other mineral contaminants. Production of pure HNTs
requires careful separation of halloysite from accompanying
minerals and therefore the economical costs of HNTs directly
depend on the initial purity of halloysite deposits. In this
respect, two main sources of HNTs are located in Northland,
New Zealand, and Utah, USA, where large deposits of high-
grade halloysite are found. Smaller or lower-grade deposits are
also found in many countries in Asia, South America, Australia,
and Europe.13 Annually, about 30 kilotonnes of halloysites are
excavated and processed into dispersed nanotubes.14
Although no direct approval of HNTs has been done by the
FDA so far, kaolin (a mineralogical group of clays to which
halloysite also belongs) is approved as an indirect food substance
generally recognised as safe (e.g. as a possible component of
paper and paperboard that contact food) under §186.1256.
Besides this, colloidal kaolin is approved as a ‘‘drug product
containing certain active ingredients offered over-the-counter’’,
§310.545, with the note that there are inadequate data to properly
assess its safety and effectiveness. Therein, kaolin is proposed as
an antidiarrheal drug product.
The fact that clays are generally recognised as safe for
humans makes biomedical use of nanoclays and in particular
HNTs highly promising. The next two sections describe advan-
tages, limitations and up-to-date achievements in utilisation of
HNTs in drug delivery and tissue engineering.
2.2. HNTs for drug delivery
2.2.1. Drug loading and release. Loading of the molecules
of interest into HNTs is determined by Si–OH and Al–OH
functional groups existing on their external and internal surfaces,
respectively. Deprotonation of silanol groups is responsible for the
negative net charge of HNTs at pH above 3. Consequently, the
anionic nature of the external HNT surface enables it to interact
with cationic compounds, while aluminol groups located on the
internal lumen surface carry positive charge and support the
loading of anionic molecules. In addition to electrostatics, inter-
action of molecules and their assemblies with HNTs might involve
hydrogen binding, van der Waals and other specific interactions.15
In general, bare HNTs exhibit weak bonding with drugs.
Chemical modification of both the inner lumen and the outer
surface is a general strategy to tune the capacity and drug delivery
performance of HNTs.16 Multiple Si–OH and Al–OH groups pre-
sent at the HNT surface provide various ways for this modification.
The lumen covered with Al–OH groups can be grafted with
organosilane and organophosphonic acid.17 For instance, the
functionalisation of HNTs with (3-aminopropyl)triethoxysilane
(APTES) introduces hydrogen-binding sites and thus enhances
the retention of drugs that are prone to form H-bonds.18
Insights into the surface modification of HNTs are substantially
described in reviews 15 and 19. The external surfaces of HNTs
can be coated with positively charged polymers. Thus, grafting
of HNTs with an amine of polyethylene glycol enhanced cellular
uptake and improved the loading of low water-soluble anti-
oxidant quercetin.20
Undoubtedly, the possibility of both loading a drug into the
lumen and grafting it to the outer surface offers some advantages
for drug delivery. HNTs are suitable for entrapment of various
drugs (analgesics,18,21 anticancer drugs,22,23 antibacterials,24 etc.)
and especially attractive for the entrapment of largemacromolecules
(genes,25 enzymes26) and nanoparticles (quantum dots,27 metal
nanoparticles,28 more examples reviewed in ref. 29), whose sizes
correlate well with the diameter of the lumen. Some recent reviews
have described the loading of molecules and particles of various
natures in more detail.24,30,31
Fig. 3 Morphology and crystal structure of halloysite nanotubes: (a) TEM
image and (b) SEM image of HNTs. Adopted with the permission from
ref. 11, copyright@ 2019 John Wiley & Sons. (c) Crystal structure and
dimensions of HNTs. Adopted with the permission from ref. 12, copyrightr
2008, American Chemical Society.
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Some recent studies have indicated that HNTs are excellent
tablet excipients (e.g. if mixed with passive components such as
microcrystalline cellulose32 and starch33 or layered with alginate
and chitosan34) due to their powder flow and compressibility
properties.
Owing to the fact that HNTs have different sites for drug
loading, it is not surprising that the release of the payload
directly depends on the way in which the drug was loaded. Thus,
the release of drugs from the lumen is mostly controlled by the
diffusion of the drug molecule from the nanotube interior that is
substantially retarded by the 1D nanotube structure. Thus, the
release of analgesics (ibuprofen,18 aspirin,35 sodium salicylate36)
from bare HNTs obeys the Fickian diffusion model. Different
modifications of the HNT lumen allow adjusting the affinity of
the drug to the HNTs and therefore controlling the release
rate.18,36 For instance, the release of ibuprofen from APTES-
modified HNTs is governed by non-Fickian diffusion due to the
additional electrostatic binding of the drug to the APTES-coated
lumen that ensures slower release compared to unmodified
nanotubes.18 Besides this, the functionalization of HNTs with
stimuli-responsive materials (e.g. pH-responsive polymers,22
thermosensitive polymers,37 magnetic nanoparticles38) allows
tuning the release profile over a much wider range, e.g. for
achieving sustained release for days38 and sometimes weeks.22
Alternatively, clogging of the ends of the tubes with polymers
(e.g. dextrin39) allows controlling the release and extending it up
to weeks. This strategy and other strategies are reviewed in
ref. 40. The release of drugs linked to the external surfaces of
HNTs strongly depends on the nature of drug–surface binding.
Since this binding often involves strong covalent interactions,41
the release of drugs from the outer surfacemight be slow, prolonged
and sometimes incomplete as was demonstrated for curcumin
covalently linked to the outer surfaces of the HNTs.41
2.2.2. Cellular uptake, cytotoxicity and in vivo studies.
Some recent studies have indicated that HNTs internalize into cells
via endocytosis. After entering the cells, HNTs are predominantly
transported into Golgi apparatus and lysosomes by microtubules
and actin filaments.42 Later, an in vitro study of HNTs functionalised
with hydrophobic coatings showed their binding to the cell
membrane and decrease in their lysosomal activity.43 These studies
open avenues for site-specific intracellular delivery using HNTs.
Numerous in vitro studies have pointed out no or a rather
low toxicity of HNTs.44,45 This was also confirmed in in vivo studies
on nematodes46 and zebrafish.47 The effect of HNTs on cells is
dose-dependent as has been shown for human cell lines.48
Recently, the size-dependent character of cellular internalisation
of HNTs (250–650 nm in length) has been demonstrated in colon
cancer cells.49 A toxic effect was reported only when high doses of
HNTs were orally administered into mice, while low and moderate
doses remain non-toxic.50 Since HNTs are non-toxic even at high
doses (concentrations of 1000 mg mL1 and higher46), they can be
suitable for nearly all administration routes. For instance, HNTs
loaded with a neurotransmitter (g-aminobutyric acid) were success-
fully attempted for delivery to the brain.51 Functionalisation of
HNTs with mucoadhesive polymers enhances their interactions
with intestinal cells and causes no cytotoxicity.52
Topical administration of HNT coatings on hair surfaces
was recently proposed. Inclusion of selected dyes or drugs into
HNTs prior to their application allows for hair coloring or
medical treatment, respectively.53
Recent in vivo studies confirmed the potential of HNTs as
effective drug delivery containers, showing that treatment with
curcumin-loaded HNTs suppresses the growth of pathogenic
bacteria in C. elegans and completely restores the longevity of
infected nematodes.54 An in vivo study of pharmacokinetics
revealed that an orally administered suspension of fluorescently
labelled HNTs is not absorbed by the intestines and eliminated
via feces within one day, while systemically administered nano-
tubes are eliminated via urine/feces within nearly 72 h.55
Notably, although in this study and some other studies23 HNTs
are intravenously injected, HNTs are non-biodegradable in
blood. Indeed, recent studies have not recommended direct
injections of HNTs that may lead to a thrombosis.45 Besides
this, a recent study demonstrated that inhalation of HNTs may
cause oxidative stress, inflammatory response, and autophagy
and therefore results in sub-chronic toxicity in mice.56 However,
this does not hinder the use of HNTs for drug delivery via
alternative routes as well as their use in tissue engineering.
2.3. HNTs for tissue engineering
In recent years, functionalisation of natural and synthetic polymer
scaffolds with nanoscale dopants has been widely attempted.
Among others, HNTs have shown great promise as an additive
to polymeric tissue engineering scaffolds due to their excellent
biocompatibility and controlled drug delivery behaviour. Impor-
tantly, HNTs can be mixed with almost any materials used for
scaffold fabrication employing traditional polymer blending
methods. It has been verified that the introduction of only a
few wt% of HNTs leads to a significant improvement of scaffold
materials. At the same time, the incorporation of extremely high
contents of HNTs (up to 80 wt%) can be safely used to form hard
tissue substitutes.57
With respect to tissue engineering applications, the use of
HNTs promotes the attachment, viability, proliferation, adhesion,
and growth of cells and improves the mechanical and thermal
stability of scaffolds, having no negative impact on the biocom-
patibility of the scaffolds.58,59 The good blood compatibility of
HNT-doped scaffolds has also been confirmed by haemolysis
tests.59 Later, blood vessel formation around HNT-doped polymer
3D scaffolds has been demonstrated.60 The scaffolds used in this
study are shown in Fig. 4.
Besides this, HNT-doped scaffolds benefit from the loading
of the nanotubes with various functional compounds such as
antimicrobial agents61,62 and the cues essential for tissue
regeneration (e.g. growth factors63).
Most of these studies have focused on in vitro evaluation
using model cell lines and stem cells. In vivo case studies are still
rather limited. Examples include (i) functionalised wound dressing
materials like HTNs/chitosan64 and HNTs/poly(L-lactide)61 which
demonstrated improved skin reepithelialization; (ii) nano-
composites for bone tissue regeneration65 wherein HNTs them-
selves stimulated osteogenic differentiation of cells and improved
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bone repair; (iii) HNT-functionalised alloys with improved corrosion
resistance for orthopaedic applications66 and (iv) aligned com-
posites with HNTs for guided nerve regeneration.63
3. Calcium carbonate
3.1. CaCO3 and its polymorphs
Anhydrous calcium carbonates exist in the form of one of the
three main polymorphs: calcite, aragonite, or vaterite. All the
polymorphs may be found in nature.67 Calcite is the major
component of carbonate rocks and hard tissues in marine
organisms (seashells) and eggshells. Although traces of vaterite
and slightly more abundant amounts of aragonite were found in
mollusc pearls, fish otoliths, and ascidians,67 calcite represents the
only stable phase of anhydrous CaCO3 and thus much dominates
over less stable vaterite and aragonite. Unfortunately, the most
common calcite is of least interest for biomedical applications due
to its non-porous structure and thus low capacity for drug loading.
As opposed to calcite, crystals of aragonite and especially vaterite
have a highly developed internal structure suitable for hosting
molecules of interest of various natures; this largely determined
the use of vaterite in nanomedicine.
Unfortunately, the occurrence of vaterite in nature is low.
Vaterite can be (bio)mineralised by some calcifying bacteria, yet
this approach is rather expensive.68 Therefore, the main source
of vaterite remains calcite. Direct transformation of calcite to
vaterite or aragonite is thermodynamically restricted;69 never-
theless, vaterite can be synthesized from calcite in a few steps.
First, CaCO3 in the form of calcite is degraded by the so-called
Solvay process in a reaction with NaCl to produce its soluble
salts (e.g. Na2CO3 and CaCl2). In much of the world, this is
the major industrial process for the production of sodium
carbonate, wherein CaCl2 is the by-product. Second, CaCO3 in
the form of vaterite can be precipitated from Na2CO3 and CaCl2
upon mixing solutions of these precursor salts.70 Nowadays,
limestone is the primary source of calcite used for the Solvay process.
Nevertheless, the use of wastematerials – seashells7 and eggshells8 –
is an excellent green alternative to rocks, which makes industrially
produced vaterite an even more attractive material in future
applications.
In view of high interest in VCC, its structure was widely
investigated.69,71 VCC comprises of small nanocrystallites
aggregated together (Fig. 5). The spaces between these nano-
crystalline form interconnected cylindrical pores that are usually
in the range of a few tens of nm. Therefore, VCC belongs to
mesoporous materials. VCC crystals have typical dimensions
ranging from 3 to 20 mm and most often have a spherical shape.
A number of recent studies have also proposed novel ways for
the fabrication of VCC nanocrystals72–74 indispensable for drug
delivery applications. The shape andmorphology of these crystals
may be tuned over a wide range using organic solvents73 or mild
water–urea mixed systems,75 polymer matrices and proteins74 or
nanoparticles.76 The porosity of the crystals can be controlled via
the variation of preparation temperature with no additives.70
The FDA has approved the use of CaCO3 (without specifying
its polymorphism) as a food additive (§582.1191), a dietary
supplement (§582.5191), a direct food substance (§184.1191),
and a colour additive for food (§73.70) and drugs (§73.1070).
Similar to kaolin clay, calcium carbonate is also mentioned in
§310.545, where it is proposed as an antidiarrheal, digestive
and weight control drug product. CaCO3 is registered as a food
additive (white food colouring) under E170 code. As a dietary
supplement, calcium carbonate may be prescribed when calcium
taken in the diet is deficient. It comes in the form of tablets,
capsules, or suspensions taken orally and sold under such brands
as Calel-Ds, Calcids, and Os-Cal 500s. The wide use of CaCO3 in
food preparation and the diet premises safe-by-design utilisation
of CaCO3 as a drug vehicle in future applications.
3.2. VCC for drug delivery
3.2.1. Drug loading and release. The mesoporous structure
of VCC serves as a host for various encapsulates ranging from
small molecules (anticancer drugs,78 anaesthetics,79 antibiotics80)
Fig. 4 (a) Photograph and (b) SEM image of pillar-shaped 3D porous
hydrogel scaffolds functionalised with 6 wt% of HNTs and SEM and
confocal images of (c and d) A549 and (e and f) Hep3B cell distributions
on them. Adopted with permission from ref. 60, copyright@ 2016, Royal
Society of Chemistry.
Fig. 5 SEM image of CaCO3 crystals demonstrating the mesoporous
nature of spherical vaterite and non-porous calcite crystals. Adopted from
ref. 77, copyrightr 2019, Elsevier.
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to macromolecules (proteins,77,81,82 growth factors,83 genes84,85)
and inorganic nanoparticles (Ag,86 TiO2,
87 Fe3O4
76,88). Importantly,
multicomponent encapsulation into VCC is also possible and
has been reported (e.g. doxorubicin and tumour-supressing
microRNA84).
Typical pores of VCC are in the range of a few tens of nm
that in general makes the encapsulation of large molecules/
particles more effective when compared to small drugs. In order
to overcome the relatively low capacity of crystals to small
molecules, the internal volume of the crystals can be filled with
a polymer matrix that has high affinity to desired drugs. This
strategy to make composite hard–soft vehicles has been widely
reported. Examples include cyclodextrin–CaCO3 hybrids designed
as carriers for hydrophobic drugs and hormones.89 Carrageenan–
CaCO3
90 and mucin–CaCO3 hybrids
91 were produced to host
doxorubicin, etc. Besides enhancing loading capacity for small
drugs, the inclusion of polymers inside crystals may also stabilise
them and slow down the VCC recrystallization to calcite that is
important for modulating the drug release profile.91
Loading of molecules into VCC can be performed under
mild conditions either during crystal growth (this approach is
usually denoted as co-precipitation or co-synthesis76,92) or by
means of post-loading into pre-formed VCC crystals (e.g. via
adsorption into crystal pores92 or a recently introduced freeze-
drying approach93). Among these approaches, adsorption and
co-synthesis are two primary methods for drug encapsulation.
Adsorption represents the most ‘‘mild’’ method suitable for the
encapsulation of labilemolecules prone to aggregation, denaturation
and the loss of activity in aggressive media.81,82,94 In contrast,
for co-precipitation mixing of drug solution with precursor salts
results in more effective entrapment and homogeneous distri-
bution of the drug inside the crystals during their growth.
However, because of more harsh conditions of crystal growth
(high ionic strength and elevated pH), much higher encapsulation
efficiencies may be accompanied by a partial loss of activity for
sensitive macromolecules,81 while small drugs are usually unaf-
fected. Finally, crystals loaded by means of adsorption are usually
prone to faster drug release than crystals loaded by co-synthesis.82
Crystal coating with lipids,95 polymers79 or polymer multi-
layers76 fabricated via polymer layer-by-layer assembly is often
proposed to reduce drug leakage and prolong drug release
kinetics. Notably, polymer multilayers are permeable for ions
and small molecules, which allows the formation of polymer
based capsules when multilayer coated VCC crystals are decom-
posed by lowering the pH or adding chelating agents (e.g.
ethylenediaminetetraacetic or citric acid). CaCO3-templated
multilayer capsules are very promising delivery vehicles; their
potential for drug delivery has been widely investigated,96–99
this also includes in vitro97 and in vivo studies.98 This article
does not consider VCC-templated capsules and beads;100 for
these topics the reader can refer to reviews 101 and 102.
The release of drugs from VCC is governed either by VCC
dissolution or by VCC recrystallization. Thus, dissolution-
mediated release occurs in case of intracellular VCC delivery,
when VCC entrapped inside lysosomes is influenced by acidic
lysosomal pH (B4.5–5.0) that promotes VCC dissolution and
results in release of the loaded molecules.78 Recent studies of
the use of VCC as an anticancer drug delivery vehicle have
shown an interesting possibility for employing VCC sensitivity
to acidic pH to target the release selectively on a tumor
microenvironment that has pH slightly below 7.95,103,104 Later,
this approach has shown to be effective not only for in vitro but
also for in vivo studies. It is worth noting that targeting an
acidic tumor microenvironment is quite a versatile approach
for anticancer therapy and has been successfully employed not
only for VCC but also for other carriers, e.g. polymeric nano-
particles;105 this supports the potency of this strategy. The pH
sensitivity of VCC crystals limits their oral administration (at least
if the crystals are not functionalized) due to the swift VCCdissolution
and the loss of the payload in the stomach (pHB 1.5–3.5).
Recrystallization-mediated release occurs due to the phase
transition of thermodynamically unstable vaterite to more
favorable and non-porous calcite with much lower surface area
and therefore much lower drug capacity.77,91,106 Recrystallization
and, as a result, release kinetics can be effectively controlled via
the use of additives that fill the pores of the crystals. For instance,
hybrids of VCC with ferromagnetic nanoparticles recrystallize to
calcite significantly more rapidly than bare vaterite crystals,
while multilayer coating or the co-precipitation of the polymers
into VCC crystals may decelerate vaterite - calcite trans-
formation.76,91 Notably, plasma proteins like bovine serum
albumin (BSA) may also significantly adsorb to the surfaces of
VCC crystals, which is of high importance for intravenous
administration. Plasma proteins not only suppress the VCC
recrystallization and therefore allow prolonged circulation of
the crystals but also minimize the neutrophil activation caused
by VCC binding to the membranes of the neutrophils.107
3.2.2. Cellular uptake, cytotoxicity and in vivo studies. Up
to now, there have been a limited number of in vitro and also
in vivo studies of employment of VCC crystals as drug delivery
vehicles. All in vitro trials show no cytotoxicity and no influence
on cell viability,108 even at enormously high concentrations.109
Intracellular VCC uptake does not cause any elevation of caspase
or Bcl-2/Bax activity, which indicates no initiation of apoptosis.110
The rate of the penetration of drug-loaded vehicles and cellular
response depend on the size and the shape of VCC.111 Although
oral delivery of VCC is limited by its high solubility in acidic
media, recent studies proposed various alternative routes of
administration.
Thus, intravenous injections were applied for the treatment
of cancer in mouse models wherein VCC crystals were used as
carriers either for doxorubicin employed in chemotherapy95,104
or for cocktails of catalase, fluorescent probes with two-photon
excitation, and traditional photosensitizers, i.e. as a platform
for photodynamic therapy.112 Both studies have revealed high
promise of the use of VCC crystals. In general, anticancer drug
delivery seems to be a major biomedical application of VCC
attempted so far. Along with the targeting the acidic tumor
microenvironment mentioned above, there are some other
advantages of VCC. One of them is simple one-step loading of
VCC with multiple functional components, e.g. combinations
of magnetic nanoparticles and anticancer drugs, which allows
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external navigation of VCC to tumor sites.113 Similarly, VCC
crystals loaded with glucose oxidase and Fe3O4 have been proposed
for chemodynamic therapy via the ultrasound-assisted Fenton
reaction.114
In view of the high promise of VCC employment in mucosal
drug delivery,99,115 a recent report demonstrated an in vivo study
of intranasal delivery into the brain using VCC pre-loaded with an
anesthetic drug.79 Interestingly, VCC crystals of different sizes
ranging from nano- to micro-dimensions have been probed in
this study, demonstrating that the micron-sized crystals ensure a
more prolonged anesthetic effect than the nano-sized ones, while
both are suitable carriers for intranasal delivery. Besides this,
transdermal,116 ocular77 and pulmonary delivery117 of VCC crystals
have been attempted.
Although the studies described above revealed the high
potential of VCC for drug delivery and laid a platform for further
clinical studies, VCC-based delivery requires much more investiga-
tions and solid basic research prior to translation into practical use.
Key milestones of further VCC development as delivery vehicles are
highlighted in the last section of this article.
3.3. VCC for tissue engineering
Nowadays, VCC crystals are primarily used for bone tissue
engineering and repair which is not surprising considering
that CaCO3 is a natural Ca-containing compound and may be
used as a mineral storage material or a source of Ca2+ for
transformation to hydroxyapatite in bone regeneration.120 VCC
has an excellent osteoinductivity, highly developed surface area
suitable for tissue growth, suitable mechanical properties and
specific binding sites for BMP-2.121 VCC plays a dual role – being
a reinforcement component that provides proper mechanical
support and a mineral source of Ca2+ essential for bone repair.
In addition, VCC may be preloaded with biofactors essential for
tissue growth and regeneration for sustained release. This has
been shown for both small drugs (e.g. tannic acid releasing for
weeks122) and biomacromolecule RNase.123
Most of the CaCO3-based scaffolds are composites made of
polymer hydrogels with VCC crystals embedded into polymer
networks and either homogeneously distributed inside gels123,124 or
representing coatings, e.g. on polymeric polycaprolactone fibers
(Fig. 6a and b).118,122
Scaffolds based on siloxane-containing VCC and biodegrad-
able polymers occupy a separate niche.83,125 VCC doped with
siloxane is used as a source for soluble silica that stimulates the
proliferation/differentiation of bone-forming cells and may be
released for months.83 In view of the topic of this article, it
seems interesting to highlight the study on the design of hybrid
bacterial cellulose and CaCO3 (that was in the form of a
vaterite–calcite mixture).126 The authors of this study high-
lighted the biodegradability and environmentally friendly fabri-
cation of such scaffolds. In another study,127 scaffolds containing
siloxane–polylactic acid–VCC hybrids with hydrated aluminum
silicate nanotubes (imogolite) allowed improving the hydrophili-
city and enhancing the cellular compatibility of the scaffolds,
which is an important issue at the early stage after implantation.
There are multiple examples of in vitro verification of the
osteogenic potential of VCC-based scaffolds. The in vivo perfor-
mance of 1 mm sized VCC crystals functionalised with heparin,
Fig. 6 3D polymer scaffolds fabricated using VCC as a coating (a and b) or a sacrificial porogen (c and d). (a) The scheme of fibrous material
mineralization under ultrasound treatment and (b) the corresponding SEM images of blank poly(e-caprolactone) fibrous material (i) and poly(e-
caprolactone) material mineralized with VCC (ii). Adopted from ref. 118, copyright@ 2017 John Wiley & Sons. (c) The scheme of microfluidics-assisted
porous alginate hydrogel fabrication and (d) CSLM images of final porous alginate scaffolds (red) formed by compact packing of VCC crystals of different
sizes (i and ii) using 5% alginate and HCl. White arrows indicate some interconnected pores. Adopted from ref. 119, copyright@ 2015 John Wiley & Sons.
Perspective NJC
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
M
ar
ch
 2
02
0.
 D
ow
nl
oa
de
d 
on
 4
/1
6/
20
20
 8
:2
8:
51
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
5646 | New J. Chem., 2020, 44, 5638--5655 This journal is©The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2020
loaded with BMP-2, and entrapped into a fibrin based hydrogel
was evaluated in repair of rabbit tibia bone. Bone defects
almost completely healed after 8 weeks.121 Electrospun scaf-
folds mineralised with VCC crystals were implanted into rats,
showing enhanced cell colonization and tissue vascularization
as well as sustained release of tannic acid.122
VCC can serve as a sacrificial template for formulation of
polymer-based scaffolds with tailor-made properties such as
well-defined internal structures and compositions. Macroporous
Ca-alginate scaffolds119,128 (Fig. 6c and d) and those made of
interconnected polymer multilayer shells129 have been reported.
VCC plays roles of a crosslinker and a porogen agent, allowing
the filling of pores with active molecules. Such scaffolds are very
soft (a few kPa), which opens new avenues to employ VCC for
soft tissue engineering.130
4. Cellulose
4.1. Cellulose-based materials
Cellulose is a natural polysaccharide that is referred to as the
most abundant biopolymer on Earth. The cellulose molecule
consists of b-D-glucopyranose rings forming monomeric units
(Fig. 7a), which in turn are organized in a cellulose network due
to intra- and inter-molecular hydrogen bonding. Cellulose
molecules possess both hydrophobic and hydrophilic parts,
making them insoluble in water.131 The molecular structure gives
rise to some beneficial properties of cellulose like biocompatibility,
biodegradability, mechanical strength and a number of hydroxyl
groups suitable for surface modification.132 Additionally, cellulose
is a semicrystalline polymer consisting of crystalline and amor-
phous parts that are characterized by strong and weak hydrogen
bonding, respectively. This opens an avenue for the preparation of
various cellulose nano-sized carriers from cellulose nanofibers by
multiple processing approaches.
Natural cellulose sources are the biomasses of plants, animals,
bacteria, and algae.133 Nowadays, plants (wood, cotton, vegetable
fibers) are the most common cellulose sources.134 Besides this,
cellulose can be extracellularly produced by some bacteria.
Currently, bacterial cellulose attracts significant attention
because it is initially free of attendant bioproducts such as
hemicelluloses, lignin, and pectin.135 In addition to the above,
industrial residues or municipal solid wastes (e.g. waste cotton
clothes and cardboard) are currently considered as new environ-
mentally friendly cellulose sources.136
The term ‘‘nanocellulose’’ implies cellulose in the form of
structures that do not exceed 100 nm in size at least in one
dimension, while in the other dimensions these structures can
reach up to a few micrometres.6 Compared to conventional
cellulose, NC exhibits enhanced relative surface area along with
tuneable mechanical, physical and chemical properties, which
makes it a promising material for a wide range of applications
including biomedical ones. Generally, depending on the origin
and processing conditions three main types of NC can be distin-
guished: cellulose nanocrystals (CNCs), nanofibers (NFs), and
bacterial cellulose (BC) (Fig. 7).
CNCs have a rod-like structure with diameters of 5–60 nm
and lengths of 100–500 nm. Typically, they are prepared by acid
hydrolysis of cellulose, resulting in the destruction of amorphous
regions, whereas the crystalline regions remain intact.137 In turn,
NFs have thicknesses up to 100 nm (or even more) and lengths up
to several micrometres. These structures are generally prepared
by enzymatic hydrolysis or high-pressure homogenization of
cellulose,138 although oxidative acid treatment may also be
employed.139 BC is also synthesized enzymatically from some
bacteria.140 It does not require additional purification steps as
it initially possesses a higher purity along with a better crystal-
linity, degree of polymerization, and mechanical stability com-
pared to other types of NC.
While HNTs and VCC have not yet been approved by the FDA
for medical use, cellulosic materials are already widely used in
medicine. Mostly, cellulose or its chemical derivatives are approved
as materials for surgery devices (e.g. nonabsorbable gauze for
internal use, §878.4450; nonresorbable gauze/sponge for external
application, §878.4014); another example is cellulose-based contact
lens intended to correct vision conditions (§886.5916). Besides this,
Fig. 7 (a) Hierarchical structure of cellulose and (b) synthesis of cellulose
nanofibers and cellulose nanocrystals; adopted from ref. 143, copyrightr
2018, Springer Nature. (c and d) SEM images of cellulose NFs and CNCs,
respectively. (c) Adopted from ref. 144, copyrightr 2013, Springer Nature.
(d) Adopted from ref. 145, copyrightr 2008, Royal Society of Chemistry.
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diluted suspensions of carboxymethylcellulose (CMC), hydroxyethyl-
cellulose (HMC) and methylcelluloses are approved as ophthalmic
demulcents under §349.12. Methylcellulose and CMC are sub-
stances generally recognised as safe (§582.1480 and §582.1745).
A number of cellulose derivatives (ethyl-, hydroxypropyl-, methyl-
ethyl-cellulose) are approved as direct additives to food for
human consumption for multipurpose use (§172-I). In regard
to this, the various types of NC seem to be promising for drug
delivery and sustainable release.
4.2. NC for drug delivery
4.2.1. Drug loading and release. The most common forms
of drug carriers based on NC materials include nanoparticles,
hydrogels, gels, membranes, and films. Nanoparticles are presented
by drug loaded CNCs. CNCs are attractive due to their shape,
biocompatibility, mechanical properties and ease of surface
functionalization or bioconjugation. Intrinsically, CNCs have a
large surface area and a negative surface charge, making them
suitable for direct binding of hydrophilic drugs to their
surfaces.141 Similarly, NFs can also be loaded with small
drugs.142 Notably, adsorption of hydrophilic drugs with a high
loading efficiency and enormous loading capacities can be
achieved (e.g. up to 80% w/w for doxorubicin141). Furthermore,
various surface modifications can be carried out on the hydroxyl
groups to improve the affinity of CNCs to drugs that would not
normally exhibit good binding, e.g. hydrophobic or uncharged
drugs. Various chemical modification approaches are reviewed
elsewhere.146,147 For, instance, CNCs modified with chitosan
can host about 14% w/w procaine hydrochloride (hydrophobic
anesthetic drug).148 CNCs modified with b-cyclodextrin were
employed for delivery of curcumin that was harboured inside
the cyclodextrin hydrophobic cavity with loading ratios 8 to 10%
with respect to CNC mass.149 Additionally, CNCs may be decorated
with metal nanoparticles for preparation of composite structures,
e.g. CNC/Ag and CNC/ZnO, have been proposed as effective anti-
microbial agents,150 whereas CNC/Au nanoparticles were used for
further immobilization of enzymes.151
Besides direct use of NC as an excipient, it is often employed
as a co-stabilizer to improve the physical–chemical properties
of a polymeric matrix that can form beads. Usually, NC has a
positive impact on the mechanical properties and the size
distribution of the beads and therefore provides a better ability
to pack the excipient, e.g. for tablet production. In such
formulations, NC plays the role of a passive filler.152
One more biomedical application of CNCs is the preparation
of gel-like structures, in particular hydro- and aero-gels. Overall,
hydrogels are three-dimensional structures formed of linked
polymer chains that are able to absorb and retain water without
being dissolved. In fact, NC-based hydrogels differ from most
other gels as their constructive elements are insoluble in water.
This results in a different mechanism of gel network formation,
which includes entanglement of NC particles or fibers followed
by physical or chemical crosslinking.153
However, CNCs themselves lack the entanglement ability
and more often are employed as fillers in gel composite structures
due to their mechanical properties. In these composite hydrogels,
the interaction of CNCs with loaded molecules (drugs) usually
does not affect the loading and release characteristics but signifi-
cantly improves the mechanical and chemical stability of the
hydrogels. Shojaeiarani et al. suggested the general classification
of CNC containing hydrogels into two main groups with respect to
their forms; the groups are bulk and injectable hydrogels.154 The
bulk hydrogels are prepared by free-radical polymerization of
monomeric units with crosslinking agents to form three-
dimensional structures. In turn, injectable hydrogels appear
as polymer solutions with the ability to gel after injection, for
instance, under physiological conditions. Moreover, they can
go through reverse sol–gel transition triggered by external
stimuli such as pH, temperature, electromagnetic fields, and
UV-light. This makes injectable hydrogels promising candidates
for drug delivery applications, as they are able to form a depot
for sustainable drug release after injection with the possibility of
remotely triggering a rapid drug release. While the use of nano-
particulate NC has relatively rarely been reported, NC-based
hydrogels in the form of films, membranes and injectable gels
have become increasingly popular for drug delivery applications,
tissue regeneration and wound healing purposes.
Regardless of the form, the release from nano- and micro-
particulate NC is mostly governed by diffusional transport that
is often influenced by swelling in the case of the hydrogels.147,155
Depending on chemical modification, the type of NC used (CNCs,
NFs or BC), the form of formulation, and the microenvironment,
the release can last from tens of minutes to a few months.147 For
instance, Li et al. prepared hybrid CNCs functionalised with
folate and pH responsive multilayers that did not release the
payload at pH 7.4 but released 95% of doxorubicin in 24 h at
pH 5.5.156 Integration of drugs into film-like matrix systems
composed of NFs ensures their storage for almost three months
at acidic pH for itraconazole and beclomethasone dipropionate
in water.157 More examples can be found in review 147.
4.2.2. Cellular uptake, cytotoxicity and in vivo evaluation.
The cellular uptake and cytotoxicity of CNCs were studied with
respect to both unmodified and functionalised NC materials.
Dong et al. studied the cytotoxicity of CNCs with nine different
cell lines and revealed no cytotoxic effects against any of the cell
lines within the concentration range.158 Similarly to HNTs,
nonphagocytic cells take up rod-like CNCs mainly through non-
specific endocytosis.158 Later, the same group demonstrated
specific cellular uptake through receptor-mediated endocytosis
of CNCs conjugated with folic acid for folate receptor-positive
cancer cells and destruction of cancer cells with internalized
CNCs by irreversible electroporation.159 Organic coatings of CNCs
can have an effect on carrier cytotoxicity.160 CNCs modified with
polymers of various natures in comparison with bare CNCs on
J774A.1 and MCF-7 cell lines have been tested. The results
indicated that cells exposed to surface coated CNCs for 24 h
did not show major changes in cell viability, membrane perme-
ability, and cell morphology. However, the authors pointed
that the longer periods of cell exposure require more careful
examination. Mahmoud et al. demonstrated the ability of
fluorescently labelled CNCs to penetrate the cell membrane with-
out losing the membrane integrity and cytotoxicity effect.161
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Interestingly, the cellular uptake was driven by the particle
surface charge and the positively charged CNCs were easily
internalized by cells unlike the negatively charged nanocrystals.
The overall toxicity of the CNCs to the human organism with
respect to the administration root and the overall dose still
have to be investigated carefully as emphasized elsewhere.162
Indeed, some reports indicate that use of NC leads to some
long-term effects, e.g. NFs non-specifically decrease the intestinal
absorption in vivo.163 It is worth mentioning that the low toxicity
of NC-basedmaterials does not guarantee the safety of chemically
modified NC. Therefore, careful evaluation of NC-derivatives
should be performed in case of every modification. For instance,
recently the hepatotoxicity of NC modified with oxalate ester has
been reported.164
The performance of injectable and bulk CNC hybrid hydro-
gels was widely investigated in vitro and in vivo. As some recent
in vivo examples, de France et al. studied tissue response and
biodistribution of CNC/poly(oligoethyleneglycol methacrylate)
injectable hydrogels.165 They found that the hydrogel is mainly
localized in the injection site and its components did not
accumulate in any organ. Additionally, the hydrogel induced
moderate inflammatory response and promoted fibroblast pro-
liferation in vivo. Magnetic bulk hydrogel beads for pH-triggered
release of anticancer drug dexamethasone in the gastro-intestinal
tract have been reported.166 Karzar Jeddi and Mahkam noted that
inclusion of 2% (wt) of CNCs improved the swelling degree, drug
loading capacity, and drug release behavior of the hydrogel compo-
sites. pH sensitive composite dialdehyde CNC/chitosan hydrogels
loaded with theophylline were tested in vitro.167
4.3. NC for tissue engineering
Cellulose-based hydrogels are extremely attractive for tissue
engineering. In recent years, various methods have been proposed
for the processing of hydrogels based on NC. The architecture of
NC can be engineered from the nano- to macro-scale that, together
with excellent biocompatibility and mechanical properties,
allows producing scaffolds particularly suitable for use in tissue
regeneration. Generally, NC-based scaffolds are composites
wherein NC is employed in combination with other polymers
or particles. The role of NC is usually in providing the required
mechanical stability and chemical resistance to hydrolytic and
enzymatic degradation.
Thus, Ghavimi et al. employed CNCs to prepare CNC/chitosan
hydrogels with mechanical properties mimicking vertebral bones
to treat vertebral compression fractures.168 Silva et al. prepared a
composite hyaluronic acid/CNC/tropoelastin hydrogel as a cell
growing substrate.169 The incorporation of CNCs improved the
hydrogel’s stability against hydrolytic and enzymatic degradation
due to the chemical bonding of CNCs and hyaluronic acid. The
resulting gels were shown to support and promote cell adhesion,
viability and growth, which is indispensable for tissue engineering
and regeneration applications. Alternatively, for cell growth appli-
cations Kumar et al. prepared polysaccharide hydrogels reinforced
with halloysites and CNCs.170 The mechanical properties of these
hydrogels can be controlled by variation of CNCs and halloysite
amount in the gel composition.
The applications of NC-based composite hydrogels in tissue
engineering are highly versatile and may cover bone tissue
engineering, cornea treatment, heart and vascular muscle
regeneration and many other relevant applications as reviewed
elsewhere.171
Currently, the development of advanced wound dressing
materials is probably one of the most attractive areas of NC-based
materials. The advanced healing strategies imply non-invasive
monitoring of tissue recovery, pain management and controlled
release of drugs accelerating regeneration and minimizing scar
formation.172
In regard to this, currently hydrogels prepared with various
forms of NC are intensively studied including those which are
sensitive to various external stimuli. Xu et al. employed CNCs
to improve the mechanical properties of thermo-responsive
chitosan/glycerol phosphate sodium injectable hydrogels.173
The resulting hydrogels were loaded with human umbilical
cord-mesenchymal stem cells that are able to produce cytokines
and growth factors promoting wound healing. The gels were
tested for cutaneous wound healing in experiments in vivo and
demonstrated accelerated wound closure and skin regeneration.
Huang et al. described an injectable hydrogel prepared using
carboxymethylchitosan and dialdehyde modified CNCs.174 The
gel demonstrated very good biocompatibility, self-healing and
on-demand solubilisation under mildly acidic conditions. The
gel was tested as a wound-healing agent in a deep partial
thickness skin burn model in vivo and was shown to be effective
for burn surface covering and treatment. Du et al. reported gel
microparticles prepared via Schiff-base reaction between carboxy-
methylchitosan and oxidized CMC and loaded with BSA or silver
sulfadiazine demonstrating alkaline and acid responsive drug
release and antibacterial properties against S. aureus and E. coli
bacteria when silver sulfadiazine was used.175 In turn, Yan et al.
prepared a pH-responsive hydrogel combining CMC, HCM and
dopamine. The resulting hydrogel demonstrated a bacteriostatic
effect that was maintained for five days.176
Another way for the preparation of a pH-responsive hydrogel
via radical polymerization was proposed by Park et al.177 The
resulting hydrogel was loaded with flavonoid naringenin to
prepare a transdermal delivery system for treatment of atopic
skin conditions disbalancing skin pH. The hydrogel effectively
wetted the skin, improving drug penetration. An interesting
approach for preparation of antimicrobial wound dressing cellulose
hydrogels was proposed by Shen et al.178 They employed meso-
porous silica nanoparticles SBA-15 coated with CaCO3 to prevent
their degradation during the preparation of an SBA-15/cellulose
composite. The sustainable antibacterial activity against S. aureus
and E. coli was figured out to be 144 h at its longest.
As NC hydrogels may act as both wound dressing materials
(Fig. 8) and scaffolds for cell culture, Loh et al. employed
bacterial NC/acrylic acid hydrogels to heal wounds requiring
exogenous cells for tissue regeneration.179 To do this, human
epidermal keratinocytes and dermal fibroblasts were enclosed
into a gel matrix. The cells were mostly attached to the hydrogel
within 4 h. In turn, the gel was shown to provide cell viability
and free transfer to the wound site. The wound healing ability
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of the cell-loaded hydrogel was estimated in experiments in vivo
in a full-thickness wound model. The wound was almost
completely closed (about 99%) in two weeks of gel treatment.
Additionally, Po¨tzinger et al. employed BC as a gene activated
matrix for prolonged release of loaded plasmids for site-specific
gene delivery.181 Plasmids can be efficiently immobilized in a
cellulose matrix providing their prolonged release up to 50 days.
The depot for sustainable and targeted delivery of plasmids may
be promising for wound healing of soft tissues due to the delivery
of plasmids encoding for growth factors of platelets, fibroblasts
or brain derived neurotrophic factors.182 The formation of hard
tissues like cartilage or bones can be promoted as well by
delivering the genes encoding for bone morphogenetic proteins,
which control bone differentiation and ossification.183 In addition,
wound dressing materials loaded with plasmids encoding for
vascular endothelial growth factors or angiogenin triggering the
formation of new blood vessels may accelerate angiogenesis.184
5. Summary and prospects
For the convenience of the reader, the key physical–chemical
properties that determine the characteristics of vehicles con-
sidered for drug delivery and tissue engineering are summar-
ized in Table 2. Each of these three vehicles can be found in
nature or synthesized from natural sources using simple and
low-cost technologies. In the age when the rapid and effective
establishment of large-scale production, which at the same
time should necessarily be ecologically friendly, is one of the
main requirements for successful translation from science to
industry, it is not surprising that research on naturally derived
HNTs, VCC and NC is actively developing. Being animal- and
plant-free materials that can be found literally beneath your
feet or isolated from wastes, HNTs, VCC and NC have high
potential to revolutionise drug vehicle production. On the other
hand, green and sustainable production is the only thing that unites
these vehicles, since each of them exhibits unique properties.
Fig. 8 Photographs of mice treated with different wound dressing
scaffolds: carboxylated cellulose nanofibers (CNFs) and two composite
CNF–gelatine scaffolds (CNF/G/Ag) functionalised with silver nanoparticles
(0.2 and 0.5 wt%, respectively). Adopted from ref. 180, copyrightr 2018
Elsevier.
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Their diverse shapes, sizes, surface charges, and mechanical
properties as well as different mechanisms of entrapment and
release of molecules give the opportunity to choose the most
suitable vehicle depending on the specific biomedical task. This
gives the vehicles equal chances for future development and
bioapplications and opens broad and new avenues for their
utilisation in biomedicine.
Although the studies of HNTs, VCC and NC toward bio-
medical applications have significantly advanced in recent
years, now it is too premature to speak about the introduction
of HNTs, VCC and NC into biomedicine. This is because this
research is still relatively new that perhaps has not even fully
reached the stage of clinical trials. While low levels of cytotoxi-
city were verified for HNTs, VCC and NC on various cell lines
and bioassays, the number of in vivo studies is still very limited.
Some other questions also remain unanswered. For instance,
the mechanisms of cellular responses to HNTs, VCC and NC
should be better described and understood. This especially
concerns VCC which potentially may cause a misbalance in
Ca2+ metabolism. Internalization mechanisms for delivery into
a cell also should be investigated. These studies should be
consistent with the design of new vehicles based on functionalised
HNTs, VCC and NC that may can expand the range of their
application, enhance cellular uptake and improve drug delivery.
In the next years, we expect the surge of in vitro and in vivo
evaluation of the performance of HNTs, VCC and NC as delivery
vehicles. Further this research might be smoothly translated to
clinical trials that will be a huge step in the development of
these naturally derived delivery vehicles.
The fact that kaolin clays, calcium carbonate and cellulose
are approved by the FDA for food supplementation and medical
uses might significantly simplify the approval of HNTs, VCC
and NC for drug delivery purposes. This gives an enormous
advantage to HNTs, VCC and NC in contrast to many other
delivery vehicles.
Together with the low production costs and availability of
the vehicles considered here, they may swiftly find their niche
in drug delivery with high potential to outpace their analogues.
Finally, tissue engineering and repair applications of HNTs,
VCC and NC deserve specific attention but other fields are
expected for future applications.
Herein, HNTs do not form the core of the scaffold but can be
used as an additive for scaffold functionalisation. Cosmetic
applications of HNTs would be expected due to their low
toxicity and ability to host and release materials in a sustained
and controlled way.
VCC is an important example for bone tissue engineering;
its future applications are expected in intracellular delivery due
to its complete degradation as well as in dentistry due to its use
as a source of calcium ions that is now achieved mostly using
amorphous CaCO3 that has no defined structure. Applications
of VCC in cosmetics would also be desirable because of its
highly controlled release and ability to encapsulate virtually any
molecules.
NC that can serve as the core material for a scaffold for
various tissues particularly stands out. At the same time,
NC-based scaffolds seem to be promising for orthopaedic and
other surgical applications due to their high biocompatibility
and an option to make films and membranes with desired
characteristics. However, more studies on controlled fabrication
and functionalisation are expected in the nearest future.
In addition to the above, new technologies for up-scalable
controlled bottom-up production of VCC and NC and new
methods for HNT purification/modification and NC isolation
from wastes are upcoming. Finally, the combination of these
natural materials will be one of the future trends that would
allow merging their properties and therefore building a better
platform for tissue growth. Scaffolds with unique active properties
demonstrating a dynamic crosstalk with a regenerating tissue are
expected as a result of hybrid materials made using combinations
of HNTs, VCC and NC. These materials belong to the third
generation of biomaterials where the dynamics of bio-signals
of extracellular matrices is recapitulated within advanced active
scaffolds.
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